Barclays PLC Lucid Diagnostics Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Barclays PLC holds 100,276 shares of LUCD stock, worth $108,298. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,276
Previous 120,002
16.44%
Holding current value
$108,298
Previous $138,000
26.81%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding LUCD
# of Institutions
84Shares Held
31.4MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.52MShares$4.89 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA4MShares$4.32 Million0.15% of portfolio
-
Two Seas Capital LP Rye, NY3MShares$3.24 Million0.06% of portfolio
-
Awm Investment Company, Inc. New York, NY2.99MShares$3.23 Million0.37% of portfolio
-
Ghisallo Capital Management LLC Greenwich, CT2.96MShares$3.2 Million0.33% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $41.7M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...